Stay updated on Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial
Sign up to get notified when there's something new on the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page.

Latest updates to the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page
- Check6 days agoChange DetectedAdded Tuberculosis as an item. Introduced a new resources link to the Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check13 days agoChange DetectedAdded Revision: v3.4.2. Removed the funding-status notice and the earlier Revision: v3.4.1.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a government-funding notice about site operations. Updated the page revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.4%

- Check28 days agoChange DetectedGlossary feature added to the page. Metadata labels updated (Last Update Submitted that Met QC Criteria; No FEAR Act Data) and the revision version bumped from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page shows a revision update from v3.3.3 to v3.3.4, indicating a minor site update with no changes to the study details, enrollment, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedDifference0.2%

Stay in the know with updates to Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Standard vs Double Dose Dolutegravir in HIV/TB Clinical Trial page.